The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Long-term Phase II results of pegylated interferon treatment in ET and PV
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of the final analysis of a single center, prospective, Phase II study (NCT00452023) of pegylated interferon alfa-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV), focusing on disease subtypes. The study results indicate that the agent is a durable treatment option for patients with these myeloproliferative neoplasms (MPNs). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
